Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet.

Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (NASDAQ: TLX) regarding potential securities fraud or unlawful business practices. The investigation follows Telix's disclosure of a subpoena from the U.S. Securities and Exchange Commission regarding the company's disclosures regarding prostate cancer therapeutic candidates. As a result, Telix's ADR price fell 10.44% to close at $14.58 per ADR on July 23, 2025. Investors who have invested in Telix are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Pomerantz LLP, a leading law firm in securities class litigation, has initiated an investigation on behalf of investors of Telix Pharmaceuticals Limited (NASDAQ: TLX). The investigation focuses on whether Telix and its officers or directors have engaged in securities fraud or other unlawful business practices [1].

The probe follows Telix's disclosure on July 22, 2025, that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC). The subpoena seeks documents and information primarily related to Telix's disclosures regarding the development of its prostate cancer therapeutic candidates [2]. This revelation prompted a significant drop in Telix's American Depositary Receipt (ADR) price, which fell by $1.70 per ADR or 10.44%, closing at $14.58 per ADR on July 23, 2025 [1].

Investors who have invested in Telix are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information and to join the class action [1]. The investigation is ongoing, and the firm is gathering information from investors who may have suffered losses due to Telix's alleged misconduct.

Hagens Berman, another prominent shareholder rights firm, has also opened an investigation into Telix, focusing on the company's statements regarding its prostate cancer therapeutic candidates. Investors with substantial losses are urged to submit their losses now, and persons with knowledge that may assist the investigation are encouraged to contact Hagens Berman [3].

The Pomerantz Firm and Hagens Berman are both renowned for their work in corporate accountability and have recovered multimillion-dollar damages awards on behalf of class members [1, 3]. Their investigations highlight the importance of transparency and accountability in corporate disclosures, particularly in the biopharmaceutical sector.

References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited--tlx-302525744.html
[2] https://www.morningstar.com/news/globe-newswire/9510022/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited-tlx
[3] https://www.morningstar.com/news/globe-newswire/9511104/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman